MEPRON Drug Patent Profile
✉ Email this page to a colleague
When do Mepron patents expire, and what generic alternatives are available?
Mepron is a drug marketed by Glaxosmithkline Llc and is included in two NDAs.
The generic ingredient in MEPRON is atovaquone. There are sixteen drug master file entries for this compound. Sixteen suppliers are listed for this compound. Additional details are available on the atovaquone profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Mepron
A generic version of MEPRON was approved as atovaquone by AMNEAL PHARMS on March 18th, 2014.
Summary for MEPRON
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 2 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 165 |
Clinical Trials: | 2 |
Patent Applications: | 6,341 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for MEPRON |
What excipients (inactive ingredients) are in MEPRON? | MEPRON excipients list |
DailyMed Link: | MEPRON at DailyMed |
Recent Clinical Trials for MEPRON
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Texas Children's Hospital | Early Phase 1 |
Baylor College of Medicine | Early Phase 1 |
William Marsh Rice University | Early Phase 1 |
Pharmacology for MEPRON
Drug Class | Antimalarial Antiprotozoal |
Anatomical Therapeutic Chemical (ATC) Classes for MEPRON
Paragraph IV (Patent) Challenges for MEPRON
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
MEPRON | Oral Suspension | atovaquone | 750 mg/5 mL | 020500 | 1 | 2009-10-20 |
US Patents and Regulatory Information for MEPRON
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Glaxosmithkline Llc | MEPRON | atovaquone | SUSPENSION;ORAL | 020500-001 | Feb 8, 1995 | AB | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
Glaxosmithkline Llc | MEPRON | atovaquone | TABLET;ORAL | 020259-001 | Nov 25, 1992 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for MEPRON
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Glaxosmithkline Llc | MEPRON | atovaquone | SUSPENSION;ORAL | 020500-001 | Feb 8, 1995 | ⤷ Try a Trial | ⤷ Try a Trial |
Glaxosmithkline Llc | MEPRON | atovaquone | SUSPENSION;ORAL | 020500-001 | Feb 8, 1995 | ⤷ Try a Trial | ⤷ Try a Trial |
Glaxosmithkline Llc | MEPRON | atovaquone | TABLET;ORAL | 020259-001 | Nov 25, 1992 | ⤷ Try a Trial | ⤷ Try a Trial |
Glaxosmithkline Llc | MEPRON | atovaquone | TABLET;ORAL | 020259-001 | Nov 25, 1992 | ⤷ Try a Trial | ⤷ Try a Trial |
Glaxosmithkline Llc | MEPRON | atovaquone | SUSPENSION;ORAL | 020500-001 | Feb 8, 1995 | ⤷ Try a Trial | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for MEPRON
See the table below for patents covering MEPRON around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Denmark | 175787 | ⤷ Try a Trial | |
Hong Kong | 103395 | Naphthoquiones for the treatment and prophylaxis of pneumocystis carinii infections | ⤷ Try a Trial |
Ecuador | SP931002 | MEDICAMENTOS | ⤷ Try a Trial |
Austria | 169215 | ⤷ Try a Trial | |
Russian Federation | 2127585 | ATOVACON IN FORM OF PARTICLES, MICROFLUIDIZED ATOVACON PARTICLES, PHARMACEUTICAL COMPOSITION CONTAINING ATOVACON PARTICLES AND METHOD OF ITS PREPARING | ⤷ Try a Trial |
Denmark | 0675711 | ⤷ Try a Trial | |
Finland | 893835 | ⤷ Try a Trial | |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for MEPRON
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
0123238 | SPC/GB95/004 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: ATOVAQUONE OPTIONALLY IN THE FORM OF A PHYSIOLOGICALLY ACCEPTABLE SALT; REGISTERED: LU 0458/94/08/0741 19940803; UK 0003/0337 19940823 |
0123238 | 95C0009 | Belgium | ⤷ Try a Trial | PRODUCT NAME: ATOVAQUONUM; NATIONAL REGISTRTION NO/DATE: 251 IS 151 F 3 19950710; FIRST REGISTRATION: LU 0458/94/08/0741 19940803 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |